Harbin%25252c%252520heilongjiang, China
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
Phase
3Span
261 weeksSponsor
First Affiliated Hospital of Zhejiang UniversityHarbin
Recruiting
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
Phase
3Span
102 weeksSponsor
Beijing InnoCare Pharma Tech Co., Ltd.Harbin, Heilongjiang
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Phase Ia is divided into two phases of dose escalation and dose extension: This part includes dose escalation and dose extension of RP903 single agent to investigate the safety, tolerability, maximum tolerated dose and pharmacokinetic (PK) characteristics of RP903 single agent. Phase Ib is the clinical indication expansion phase, and the primary purpose of this phase is to evaluate the initial safety and anti-tumor efficacy in a selected indication target population. After determining RP903 monotherapy RP2D in Phase Ia, SMC will select four advanced malignant tumors with PIK3CA mutations (cervical cancer, endometrial cancer, breast cancer, and ovarian cancer) as indications for clinical expansion studies based on phase Ia efficacy, safety, and pharmacokinetic (PK) data. The dose was determined according to the results of the dose escalation phase and the dose extension phase.
Phase
1Span
160 weeksSponsor
Risen (Suzhou) Pharma Tech Co., Ltd.Harbin
Recruiting
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Phase
1/2Span
89 weeksSponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Harbin, Heilongjiang
Recruiting
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Phase
2Span
155 weeksSponsor
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Harbin, Heilongjiang
Recruiting
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Phase
2Span
108 weeksSponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Harbin, Heilongjiang
Recruiting
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
Primary objective: to evaluate the efficacy of RC148 injection as monotherapy or combination therapy in patients locally advanced or metastatic non-small cell lung cancer;
Phase
1Span
125 weeksSponsor
RemeGen Co., Ltd.Harbin, Heilongjiang
Recruiting
Study on c-Met Targeted PET/CT Imaging in NSCLC
In the study, NSCLC patients with different c-Met activation status (c-Met overexpression, MET exon 14 skipping mutation, MET amplification, MET wild type) confirmed by pathology or gene detection will receive 18F-TSPF PET/CT and 18F-FDG PET/CT respectively. The goal of the study is to evaluate specificity and accuracy of 18F-TSPF as a novel PET radiotracer to detect c-Met activation status and potentially identify c-Met-TKIs benefited NSCLC patients.
Phase
N/ASpan
88 weeksSponsor
Xilin SunHarbin, Heilongjiang
Recruiting
Healthy Volunteers
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
Phase
3Span
146 weeksSponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Harbin, Heilongjiang
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
Phase
1/2Span
78 weeksSponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Harbin, Heilongjiang
Recruiting